Lv1
50 积分 2024-10-17 加入
Case Study #6: [177Lu]Lu-DOTA-JR11: A Somatostatin Receptor Subtype 2 Antagonist for Radiopharmaceutical Therapy
10小时前
已完结
The Role of [177Lu] Lu-Satoreotide Tetraxetan in Somatostatin Receptor-Positive Neuroendocrine Tumors
1天前
求助中
The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma
10天前
已完结
Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial
1个月前
已完结
Strategies to improve the physicochemical properties of peptide-based drugs
1个月前
已完结
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
2个月前
已完结
Affinity analysis of somatostatin and somatostatin receptor by surface plasmon resonance
2个月前
已完结
Therapeutic uses of somatostatin and its analogues: Current view and potential applications
2个月前
已完结
Somatostatin and its Analogs
2个月前
已完结
A novel antagonist anti‐cMet antibody with antitumor activities targeting both ligand‐dependent and ligand‐independent c‐Met receptors
2个月前
已完结
皖公网安备34019202002308
